Shares of Natco Pharma moved higher in early trade on Wednesday after the pharmaceutical company announced the launch of Pomalidomide Capsules in the United States in partnership with Breckenridge Pharmaceutical, Inc.. The product is a generic version of Pomalyst, originally marketed by Celgene.
The stock rallied more than 2% following the announcement as investors reacted to the company’s entry into a high-value oncology drug segment in the US market.
Natco Pharma said that Pomalidomide Capsules are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression on or within 60 days of completing their last treatment.
The drug is also approved for the treatment of AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients diagnosed with Kaposi sarcoma.
The capsules will be available in four strengths — 1mg, 2mg, 3mg, and 4mg — and will primarily be distributed through specialty pharmacies and clinics across the United States. Pomalidomide is a thalidomide analogue widely used in the treatment of advanced-stage multiple myeloma.
According to industry sales estimates, Pomalidomide Capsules recorded US sales of around USD 3.2 billion for the 12-month period ending September 2025, highlighting the large market opportunity for generic manufacturers entering the segment.